1. Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer.
- Author
-
Raynes, George, Stares, Mark, Low, Samantha, Haron, Dhania, Sarwar, Hussain, Abhi, Dhruv, Barrie, Colin, Laird, Barry, Phillips, Iain, and MacKean, Melanie
- Subjects
THERAPEUTIC use of monoclonal antibodies ,LUNG cancer ,BIOMARKERS ,IMMUNE checkpoint inhibitors ,CONFIDENCE intervals ,INFLAMMATION ,RETROSPECTIVE studies ,ACQUISITION of data ,REGRESSION analysis ,TREATMENT effectiveness ,MEDICAL records ,DESCRIPTIVE statistics ,RESEARCH funding - Abstract
Simple Summary: Immune checkpoint inhibitors offer the chance for the durable disease control of advanced/metastatic non-small-cell lung cancer (NSCLC). However, they come with the risk of immune-related adverse events (irAEs) which may be severe or life-threatening, or lead to long-term toxicity. We confirm that the occurrence of irAEs is associated with improved survival outcomes in patients with NSCLC treated with pembrolizumab. These survival benefits are only seen in patients with particular irAEs, or mild irAEs. Significantly, we account for the time-dependent association between time on treatment and the development of irAEs. Low levels of systemic inflammation, as defined by simple biomarkers of systemic inflammation, have previously been shown to predict the occurrence of irAEs. However, we find that their predictive power is confounded by their independent prognostic value. We suggest that these findings are taken into account by other studies investigating potential biomarkers of irAE risk. Background: Pembrolizumab monotherapy for non-small-cell lung cancer (NSCLC) expressing PD-L1 ≥ 50% doubles five-year survival rates compared to chemotherapy. However, immune-related adverse events (irAEs) can cause severe, long-term toxicity necessitating high-dose steroids and/or treatment cessation. Interestingly, patients experiencing irAEs demonstrate better survival outcomes. Biomarkers of systemic inflammation, including the Scottish Inflammatory Prognostic Score (SIPS), also predict survival in this patient group. This study examines the relationship between inflammatory status, irAEs, and survival outcomes in NSCLC. Methods: A retrospective analysis was conducted on patients with NSCLC expressing PD-L1 ≥ 50% receiving first-line pembrolizumab monotherapy at a large cancer centre in Scotland. Regression analyses were conducted to examine the relationship between SIPS, irAEs, and survival. Results: 83/262 eligible patients (32%) experienced an irAE. Dermatological, endocrine, gastrointestinal, and hepatic, but not pulmonary, irAEs were associated with prolonged PFS and OS (p <= 0.011). Mild irAEs were associated with better PFS and OS in all patients, including on time-dependent analyses (HR0.61 [95% CI 0.41–0.90], p = 0.014 and HR0.41 [95% CI 0.26–0.63], p < 0.001, respectively). SIPS predicted PFS (HR 1.60 [95% CI 1.34–1.90], p < 0.001) and OS (HR 1.69 [95% CI 1.41–2.02], p < 0.001). SIPS predicted the occurrence of any irAE in all patients (p = 0.011), but not on 24-week landmark analyses (p = 0.174). The occurrence of irAEs predicted favourable outcomes regardless of the baseline inflammatory status (p = 0.015). Conclusion: The occurrence of certain irAEs is associated with a survival benefit in patients with NSCLC expressing PD-L1 ≥ 50% receiving pembrolizumab. We find that the association between low levels of systemic inflammation and the risk of irAEs is confounded by their independent prognostic value. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF